Oncolinx's Grant

Oncolinx raised a round of funding on April 02, 2016. Investors include Horizon 2020.

Oncolinx is developing antibody-drug conjugates, which carry an Azonafide cytotoxin attached to an antibody specifically to tumor cells and not healthy cells, thereby avoiding many of the side effects…

Articles about Oncolinx's Grant: